INFORMAZIONI SU QUESTO EPISODIO
If BPC-157, TB-500, KPV, MOTS-C and similar peptides are so interesting, why don't we have giant randomized human trials?
This episode looks at the less dramatic—and more important—answer: clinical trials require a sponsor, regulatory strategy, manufacturing package, defined indication, safety program, and a very large amount of money. For old, easily copied, poorly protected, or commercially fragmented compounds, the incentive to fund definitive trials may be weak.
John also explains why that does not excuse the evidence gap. "No Phase 3 trial" is not proof that a peptide works. It simply means confidence should remain limited until better evidence exists.
Educational only. Not medical advice.
Inglese
Stati Uniti
TRASCRIZIONE 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
CERCA TRA GLI EPISODI PASSATI
Cerca gli episodi passati di Peptides Explained.
ALTRI EPISODI IN QUESTO PODCAST
Glutathione gets called the "master antioxidant," and the underlying biology really is important. But does that mean oral supplements, liposomal products or glutathione IVs deliver the sweeping detox, energy, immune and anti-aging benefits often attached to them?
John breaks down glutathione biolo…
Follistatin can bind myostatin—one of the body's major restraints on skeletal-muscle growth. Animal studies are dramatic, and small human gene-therapy studies have produced encouraging signals in serious muscle disease.
But is a vial labeled "Follistatin-344" equivalent to the therapy used in thos…
Download The Peptide App at ThePeptide.App/Explained
For more information on research peptides check out PeptidesExplained.info/OfflinePeptides
A peptide…in a pill?
Icotyde, or icotrokinra, is an FDA-approved oral peptide designed to block the IL-23 receptor in moderate-to-severe plaque psoriasi…
For more information on Research Peptides go to PeptidesExplained.info/OfflinePeptides
Is taking smaller GLP-1 doses multiple times per week actually "microdosing"? Not necessarily.
This episode separates split dosing from true dose reduction and explains the pharmacokinetic logic using semagluti…
FLGR-242 is being called a smarter, longer-acting follistatin. John examines the advertised construct, the activin-sparing and 19-day half-life claims, the difference between pathway evidence and product evidence, and why transformation photos cannot establish pharmacology or safety.
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da John Garrett, che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.
MODIFICA
Grazie, ci hai aiutato a mantenere aggiornato il database dei podcast.
